Cancer-Associated PainNCT04875286
Patient Reported Symptom Control With THC or CBD Use
An observational study of Cancer-Associated Pain and Hematopoietic and Lymphoid Cell Neoplasm, run by M.D. Anderson Cancer Center at 2 sites in United States.
Trial summary
This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer-Associated Pain, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Electronic Health Record Review and Questionnaire Administration
- How many people
- 200 participants
- Where
- 2 sitesUnited States
- Study dates
- 3 Feb 2021to 2 Feb 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)
Who may be able to join
- Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)
- Patients must be primary residents of Texas or Arizona
- Patients able to speak and read English
- Patients are 18 years old and above
- Patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl)
- Patients who have used in the past 3 months or are using alternative botanical pain management while under prescription opioids
Who cannot join
- Patients who are not able to speak or read English
- Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process
- Patients who have not used medical marijuana and/or CBD products
- Patients who do not have cancer
- Patients who do not have cancer-associated pain
- Patients who are not taking opioids
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
M D Anderson Cancer Center
Houston, Texas, 77030
About this study
This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.
Read the detailed description
PRIMARY OBJECTIVE:
- To determine the patient's reported preference for cancer pain improvement with opioids, opioids with delta-9-tetrahydrocannabinol (THC)-marijuana and/or opioids with cannabidiol (CBD).
SECONDARY OBJECTIVES:
- To determine the association between perception of cancer-related symptom relief and use of THC-marijuana and/or CBD.
II. To compare patient perception of THC-marijuana and/or CBD versus (vs.) cancer treatments in treatment of cancer.
III. To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD.
IV. To evaluate patient reported concerns while using THC-marijuana and/or CBD. V. To evaluate patient attitude of dosing, forms and use of THC-marijuana and/or CBD.
VI. To evaluate demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD.
VII. To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state.
VIII. To explore the patient reported preference of THC-marijuana and CBD for cancer pain and symptom relief of patients in a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson.
OUTLINE:
Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
- Conditions
- Cancer-Associated Pain, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Being tested
- Electronic Health Record Review, Questionnaire Administration
- Medical subject headings
- Cancer Pain, Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electronic Health Record ReviewOther
Medical records reviewed
Questionnaire AdministrationOther
Complete questionnaires
| Study group | Role | What they receive |
|---|---|---|
| Observational (medical record review, questionnaires)) | Patients' medical records are reviewed and then complete questionnaires over 27 minutes. Receives: Other: Electronic Health Record Review; Other: Questionnaire Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief
Will be calculated and reported along with a 95% confidence interval.
Measured: through study completion, an average of 1 year
Secondary outcomes (8)
Perception of cancer-related symptom relief
Will be associated with use of THC-Marijuana and/or CBD. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both.
Measured: through study completion, an average of 1 year
Patient perception of THC-marijuana and/or CBD
Compared to cancer treatments in treatment of cancer. Will be evaluated by generalized linear mixed models to account for the dependency among those patients who have used/are using both.
Measured: through study completion, an average of 1 year
To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Measured: through study completion, an average of 1 year
To evaluate patient reported concerns while using THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Measured: through study completion, an average of 1 year
Patient attitude of dosing, forms and use of THC-marijuana and/or CBD
Patient reported outcomes will be summarized by frequency and proportion.
Measured: through study completion, an average of 1 year
Demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD
Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate.
Measured: through study completion, an average of 1 year
To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state.
Differences will be explored.
Measured: through study completion, an average of 1 year
Patient reported preference of THC-Marijuana and CBD for cancer pain and symptom relief of patients
Will be explored between a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson. Will be evaluated by Wilcoxon rank sum (Kruskal-Wallis) test or chi-square (Fisher's exact) test, when appropriate. To further evaluate these associations, univariate and multivariable logistic regression models will be fitted. Multiple comparisons will be adjusted where appropriate.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2021
- Study start3 Feb 2021
- Primary completion2 Feb 2027 (estimated)
- Study completion2 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer-Associated PainStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kimberson C Tanco, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04875286
- Sponsor's protocol ID
- 2019-0753
- Other IDs
- NCI-2021-02853, 2019-0753
- Status last verified
- Sep 2026
- First submitted
- 22 Apr 2021
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Reported Symptom Control With THC or CBD Use
- ClinicalTrials.gov ID
- NCT04875286
- Acronym / sponsor ID
- 2019-0753
- Conditions
- Cancer-Associated Pain, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 3 Feb 2021 (actual)
- Primary completion
- 2 Feb 2027 (estimated)
- Study completion
- 2 Feb 2027 (estimated)
- First posted
- 6 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.
Detailed description
PRIMARY OBJECTIVE:
- To determine the patient's reported preference for cancer pain improvement with opioids, opioids with delta-9-tetrahydrocannabinol (THC)-marijuana and/or opioids with cannabidiol (CBD).
SECONDARY OBJECTIVES:
- To determine the association between perception of cancer-related symptom relief and use of THC-marijuana and/or CBD.
II. To compare patient perception of THC-marijuana and/or CBD versus (vs.) cancer treatments in treatment of cancer.
III. To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD.
IV. To evaluate patient reported concerns while using THC-marijuana and/or CBD. V. To evaluate patient attitude of dosing, forms and use of THC-marijuana and/or CBD.
VI. To evaluate demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD.
VII. To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state.
VIII. To explore the patient reported preference of THC-marijuana and CBD for cancer pain and symptom relief of patients in a Supportive Care Center vs. Integrative Medicine Center at University of Texas (U.T.) MD Anderson.
OUTLINE:
Patients' medical records are reviewed and then complete questionnaires over 27 minutes.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observational (medical record review, questionnaires)) | – | Other: Electronic Health Record Review, Other: Questionnaire AdministrationPatients' medical records are reviewed and then complete questionnaires over 27 minutes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)
Key inclusion criteria (6 listed)
- Patients (inpatient or outpatient) seen by the Palliative Care and Integrative Medicine teams at The University of Texas MD Anderson Cancer Center (Texas) and the Palliative Care team at Banner MD Anderson Cancer Center (Arizona)
- Patients must be primary residents of Texas or Arizona
- Patients able to speak and read English
- Patients are 18 years old and above
- Patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl)
Key exclusion criteria (6 listed)
- Patients who are not able to speak or read English
- Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process
- Patients who have not used medical marijuana and/or CBD products
- Patients who do not have cancer
- Patients who do not have cancer-associated pain
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electronic Health Record ReviewMedical records reviewed | Other | Observational (medical record review, questionnaires)) |
| Questionnaire AdministrationComplete questionnaires | Other | Observational (medical record review, questionnaires)) |
Primary outcome
Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief
Time frame: through study completion, an average of 1 year
Will be calculated and reported along with a 95% confidence interval.
8 secondary outcomes
Perception of cancer-related symptom relief
Time frame: through study completion, an average of 1 year
Patient perception of THC-marijuana and/or CBD
Time frame: through study completion, an average of 1 year
To evaluate patient report of adverse effects experienced while using THC-marijuana and/or CBD
Time frame: through study completion, an average of 1 year
To evaluate patient reported concerns while using THC-marijuana and/or CBD
Time frame: through study completion, an average of 1 year
Patient attitude of dosing, forms and use of THC-marijuana and/or CBD
Time frame: through study completion, an average of 1 year
Demographic, physical and psychosocial factors that influence patient perception and attitudes of THC-marijuana and/or CBD
Time frame: through study completion, an average of 1 year
To explore the difference of patient perception of THC-marijuana and CBD in cancer centers in a legalized vs. a non-legalized state.
Time frame: through study completion, an average of 1 year
Patient reported preference of THC-Marijuana and CBD for cancer pain and symptom relief of patients
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Cancer-Associated Pain
Recruiting
Cancer Pain Management Using a Web-based Intervention
Cancer of Breast, Depressive Symptoms
Not yet recruitingPhase 1/2
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
Intractable Pain, Palliative Care
Active, not recruiting
A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Active, not recruitingPhase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
Breast Cancer, Arthralgia
Active, not recruitingPhase 2
Psilocybin in Cancer Pain Study
Opioid-Related Disorders, Pain Management
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kimberson C Tanco principal investigator
M.D. Anderson Cancer Center
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer-Associated Pain and Hematopoietic and Lymphoid Cell Neoplasm, run by M.D. Anderson Cancer Center at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients who prefer opioids with THC-marijuana and/or opioids with cannabidiol (CBD) to opioids alone for their cancer pain relief (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.